Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Kohl's Corporation — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Kohl's Corporation trades at $21.11 (market cap $2.39B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 13× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| GEHC | KSS | |
|---|---|---|
Market Cap | $31.07B | $2.39B |
Volume | 3,443,020 | 4,591,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $24.71 |
52-Week Low | $59.48 | $11.72 |
Enterprise Value | $39.53B | $7.99B |
Dividend Yield | 0.23% | 2.37% |
Typical Hold Time | — | 48 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Kohl's (KSS) trades at $21.15, down slightly by 0.09% on the day, with the stock showing bullish technical signals from moving averages. The company has beaten earnings expectations for three consecutive quarters, including a significant Q2 2026 beat of $1.28 EPS versus $0.58 expected. Despite declining revenues, Kohl's maintains attractive valuation metrics with a P/E of 9.06 and P/S of 0.16, while recent management changes and operational improvements provide potential catalysts.
The investment case centers on deep value metrics and operational turnaround potential, though persistent revenue declines and competitive pressures remain key risks. Analyst sentiment is mixed with 30% buy ratings but a consensus price target of $15.50 below current levels, suggesting cautious optimism about the company's ability to stabilize sales and improve profitability in a challenging retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
